Elotuzumab

N/A

Report date: 2026/04/21 20:00:18
First In Class

Base Information

Drug NameElotuzumab
Drug Alias Name依洛妥珠单抗Elotuzumabum依洛珠单抗埃罗妥珠单抗Empliciti +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunostimulantsSLAM family member 7 modulators
TargetsSLAM family member 7
Therapy Area/IndicationsPrimary MyelofibrosisThrombocythemia, EssentialSmoldering Multiple Myeloma +[9] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/11/30
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAbbvie IncBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteBristol Myers Squibb SrlcompanyThe University Of Texas MD Anderson Cancer Center +[8] 
Inactive CompaniesAbbott LaboratoriesWake Forest University Health SciencesNational Cancer Institute +[4] 
Active IndicationsPrimary MyelofibrosisThrombocythemia, EssentialSmoldering Multiple Myeloma +[7] 
Inactive IndicationsHematologic NeoplasmsLymphoma

Other Information

ATC CodeL01XC23
Related LinksWikipediaDrugBankKEGG